A share price of United Therapeutics Corp [UTHR] is currently trading at $370.74, up 4.93%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The UTHR shares have gain 4.68% over the last week, with a monthly amount glided 2.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on July 11, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also boosted its price target to $321 from $310. Previously, Goldman upgraded its rating to Neutral on February 12, 2024, and elevated its price target to $215. On February 05, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $330 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $309 on December 08, 2023. UBS initiated its recommendation with a Buy and recommended $320 as its price target on December 06, 2022. Goldman started tracking with a Sell rating for this stock on December 05, 2022, and assigned it a price target of $230. In a note dated October 11, 2022, Morgan Stanley initiated an Overweight rating and provided a target price of $288 on this stock.
United Therapeutics Corp experienced fluctuations in its stock price throughout the past year between $210.64 and $417.82. Currently, Wall Street analysts expect the stock to reach $458 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $370.74 at the most recent close of the market. An investor can expect a potential return of 23.54% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
Trailing Twelve Months sales for United Therapeutics Corp [NASDAQ:UTHR] were 2.76B which represents 22.89% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.46%, Pretax Profit Margin comes in at 0.52%, and Net Profit Margin reading is 0.4%. To continue investigating profitability, this company’s Return on Assets is posted at 0.16, Equity is 0.19 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 357.02 points at the first support level, and at 343.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 377.67, and for the 2nd resistance point, it is at 384.61.
Ratios To Look Out For
To put it in perspective, the Current Ratio for United Therapeutics Corp [NASDAQ:UTHR] is 4.58. As well, the Quick Ratio is 4.41, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 6.01, the price to book ratio is 2.71 and price to earnings (TTM) ratio is 16.28.
Transactions by insiders
Recent insider trading involved BENKOWITZ MICHAEL, PRESIDENT AND COO, that happened on Feb 10 ’25 when 10000.0 shares were sold. Officer, Michael Benkowitz completed a deal on Feb 10 ’25 to buy 40000.0 shares. Meanwhile, PRESIDENT AND COO BENKOWITZ MICHAEL sold 10000.0 shares on Feb 03 ’25.
